Welcome to our dedicated page for Moleculin Biotech SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Moleculin Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Moleculin Biotech's regulatory disclosures and financial reporting.
On August 3, 2026, Moleculin Biotech, Inc. Chief Financial Officer Jonathan P. Foster purchased 293,333 shares of common stock and 879,999 Series I Warrants in a public offering at a combined price of $0.75 per one share of common stock and three accompanying warrants. Following these transactions, he directly held 305,673 shares of common stock and 1,027,717 Series I Warrants to purchase common stock, which are reported with an expiration date of August 3, 2031.
Moleculin Biotech, Inc. director, CEO and President Walter V. Klemp reported acquiring 533,333 shares of common stock in a public offering, together with Series I warrants to purchase 1,599,999 shares. The securities were bought at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants. Following these transactions, he directly holds 564,340 common shares and 1,926,335 Series I warrants, which are exercisable for common stock and expire on August 3, 2031.
Moleculin Biotech, Inc. reports that Chief Science Officer Donald H. Picker purchased 173,333 shares of common stock and Series I Warrants to purchase 519,999 shares on August 3, 2026, in a public offering at a combined purchase price of $0.75 per one share and three warrants. Following these transactions, he directly holds 174,086 common shares and 539,595 Series I Warrants.
Moleculin Biotech entered placement agency and securities purchase agreements for a public offering of 12,376,667 shares of common stock or pre-funded warrants and Series I common stock purchase warrants to buy up to 37,130,001 shares. The combined public offering price is $0.75 per share (or pre-funded warrant) and accompanying warrant, generating approximately $9.3 million in gross proceeds before fees and expenses. The sale closed on August 3, 2026 under an effective Form S-1 registration statement.
The pre-funded warrants are exercisable at $0.001 per share until fully exercised, while the common warrants are exercisable at $0.75 per share for five years after the initial exercise date, subject to 4.99%–9.99% beneficial ownership limits and an exercise price adjustment feature with a $0.21 floor. Net proceeds are intended to advance the Annamycin program through clinical development and for working capital. The company agreed to restrictions on additional equity issuances and variable rate transactions, 60‑day lock-ups for directors and officers, a 6.5% cash fee plus up to $100,000 of expenses to the placement agent, and a 1.0% fee to a financial advisor.
Moleculin Biotech, Inc. is conducting a reasonable best efforts public offering of up to 11,088,334 shares of common stock at $0.75 per share together with 37,130,001 Series I common warrants, plus up to 1,288,333 pre-funded warrants offered in lieu of shares for certain large investors. Each share or pre-funded warrant is sold with three common warrants, each exercisable at $0.75 for five years, with anti-dilution down to a $0.15 floor. Maximum gross proceeds are $9.28 million, with estimated net proceeds of about $8.5 million, before any warrant exercises. The company plans to use the proceeds primarily to advance its lead drug candidate Annamycin in the pivotal Phase 2/3 MIRACLE trial for relapsed/refractory AML and for working capital. The offering has no minimum, no escrow, and may close with reduced proceeds, increasing financing risk and dilution. Common shares outstanding are expected to rise from 7,100,713 to 18,189,047 (or 19,477,380 if all pre-funded warrants are exercised), excluding any exercise of the new common warrants.
Moleculin Biotech is reporting updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory acute myeloid leukemia. With 62 subjects evaluable, the blinded complete remission (CR) rate is 24% and the composite complete remission (CRc) rate is 37%.
Of these 62 subjects, 30 (48%) had previously received a venetoclax-based regimen; in this subgroup, blinded CR and CRc rates are 23% and 37%, similar to the overall evaluable population. The analysis remains blinded and includes control-arm patients, and is therefore expected to be below unblinded Annamycin-arm results reported in June, when CRc reached 50% and 57% in the two Annamycin arms versus 29% for control after a single cycle. Enrollment stands at 74 of 90 Part A subjects, with the Company expecting to treat the 90th subject in September 2026 and to unblind comprehensive Part A data in the December 2026 to February 2027 timeframe. Across the trial, the Company reports no evidence of cardiotoxicity, and notes that Annamycin holds Fast Track Status and Orphan Drug Designations for relapsed or refractory AML.
Moleculin Biotech, Inc. is conducting a reasonable best efforts public offering of up to 4,566,210 shares of common stock, together with Series I common warrants and alternative pre-funded warrants. The registration also covers up to 18,264,840 shares of common stock underlying the pre-funded and common warrants.
The assumed combined public offering price is $2.19 per share (or pre-funded warrant) and accompanying three common warrants, matching the July 27, 2026 Nasdaq closing price. If all securities are sold at this price, net proceeds are estimated at $9.1 million, to advance Annamycin through clinical development and for working capital. Common stock outstanding would increase from 7,100,713 to 11,666,923 shares, with as adjusted net tangible book value of $1.32 per share and immediate dilution of $0.87 per share to new investors.
The offering has no minimum, no escrow and may close with significantly less capital raised, potentially limiting the intended use of proceeds. Common warrants become exercisable only after any required Warrant Stockholder Approval; without such approval they will not be exercisable and will have no value. Interim data from the pivotal MIRACLE Phase 2/3 trial in relapsed/refractory AML showed higher complete remission rates in Annamycin arms versus control, but results are based on a limited sample, are not yet statistically significant and may not predict final outcomes.
Moleculin Biotech, Inc. is registering a reasonable best efforts primary offering of up to 4,566,210 shares of common stock, up to 4,566,210 pre-funded warrants, and 13,698,630 Series I common warrants at an assumed combined price of $2.19 per share or pre-funded warrant plus warrants.
Each share or pre-funded warrant is sold with three common warrants, exercisable at $2.19 for five years beginning on the later of closing or any required Warrant Stockholder Approval; without such approval the common warrants will not be exercisable and will have no value. There is no minimum offering amount, no escrow, and Roth Capital Partners acts as placement agent for a 7% cash fee.
Assuming all securities are sold at the assumed price, Moleculin estimates net proceeds of about $9.1 million, to be used to advance its lead drug Annamycin and for working capital. Shares outstanding would increase from 5,336,350 to 9,902,560, excluding warrant, option and RSU overhang.
The company is conducting the pivotal Phase 2/3 MIRACLE trial in relapsed/refractory AML. A June 2026 interim analysis in 45 patients showed complete remission rates of 43% and 36% in two Annamycin arms versus 12% in control, and composite CR rates of 50% and 57% versus 29%. These results were not statistically significant; the independent data monitoring committee recommended continuing both Annamycin dose arms, and the trial remains designed for 80% power at final analysis. The company states that these interim data may not predict final outcomes and that it will require significant additional financing, beyond this offering, to continue funding its clinical programs.
Moleculin Biotech, Inc. is conducting a reasonable best efforts primary offering of up to 4,566,210 shares of common stock, together with up to 4,566,210 pre-funded warrants, up to 13,698,630 common warrants, and up to 18,264,840 shares underlying those warrants. Each share or pre-funded warrant is offered with three common warrants at an assumed combined price of $2.19.
The company is a late-stage pharmaceutical developer focused on Annamycin (naxtarubicin), a “next‑generation” anthracycline in a pivotal Phase 2/3 MIRACLE trial for relapsed/refractory AML. Interim unblinded results from 45 patients showed higher complete and composite remission rates in both Annamycin arms versus control, but without statistical significance at this stage; the independent monitoring committee recommended continuing the trial.
At the assumed $2.19 price and full take-up, Moleculin projects net proceeds of about $9.1 million, intended mainly to advance Annamycin and for working capital. Common shares outstanding would increase from 5,336,350 to 9,902,560 before any warrant exercises, and new investors would incur immediate book-value dilution.